MedTrace Logo

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

NCT00198133 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2019-07-22

Study results available
· View outcomes & findings →

Summary

To study the efficacy of Alimta as a single agent in thymic cancers

Conditions

  • Thymoma
  • Thymic Carcinoma

Interventions

DRUG

Premetrexed (Alimta)

Pemetrexed will be 500 mg/m2 IV every 3 weeks

Sponsors & Collaborators

  • Patrick Joseph Loehrer Sr.

    lead OTHER

Principal Investigators

  • Patrick Loehrer, M.D. · Indiana University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-12-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00198133 on ClinicalTrials.gov